TRB-001 vaccine safely induces high-titer, high-avidity alpha-synuclein antibodies in Parkinson's patient, stabilizing MDS-UPDRS.
Background
Parkinson's disease (PD) is a debilitating neurodegenerative disorder lacking a cure, characterized by the abnormal aggregation of alpha-synuclein (aSyn) into Lewy bodies. Current treatments primarily manage symptoms, but do not address the underlying pathology of aSyn accumulation. Developing an active immunotherapy to target aggregated aSyn is a critical strategy to halt or reverse disease progression. TRB-001 represents a novel class of peptide/protein conjugate vaccines designed to specifically target and activate antigen-presenting cells to clear pathological aSyn.
Study Design
A 33-year-old male diagnosed with Parkinson's disease (Hoehn & Yahr stage 1) received TRB-001 via four administrations at weeks 0, 4, 8, and 34. The patient was on a complex regimen of Levodopa/Benserazide, Rotigotine, and Rasagiline, with a Levodopa equivalent daily dose (LEDD) of 940 mg, and also experienced impulse control disorder. The study assessed safety, immunological parameters (antibody titer, avidity), and clinical outcomes using the Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) over an observation period of 53 weeks.
Results
Vaccinations with TRB-001 were consistently well tolerated, with no significant adverse events reported. The treatment successfully induced a high-titer, long-lived alpha-synuclein-specific antibody (Ab) response in the patient. This increase in Ab titer was associated with a reduction in plasma levels of alpha-synuclein, suggesting effective target engagement within the body. A booster dose at week 34 elicited a robust recall-type Ab titer increase and significantly triggered avidity maturation, improving antibody binding strength by a factor of 7.8. These induced antibodies demonstrated a high degree of selectivity, reacting preferentially with aggregated alpha-synuclein by a factor of 30, and were found to react specifically with tissue derived from Parkinson's disease brain lysates. Clinically, the patient's MDS-UPDRS score remained essentially stable throughout the 53-week observation period.
Notably, at the time of the boost, the patient's symptomatic PD therapy was simplified, reducing his LEDD from 940 mg to 532 mg, which also led to the complete resolution of his impulse control disorder symptoms.
Key Findings
- TRB-001 vaccine was well tolerated in a Parkinson's disease patient.
- Induced a high-titer, long-lived alpha-synuclein-specific antibody response.
- Antibody titer increase correlated with reduced alpha-synuclein plasma levels.
- Boost administration triggered 7.8-fold avidity maturation of antibodies.
- Antibodies showed 30-fold selectivity for aggregated alpha-synuclein and reacted with PD brain tissue.
- Patient's
MDS-UPDRSscore remained stable over 53 weeks, and symptomatic medication was reduced.
Why It Matters
This case report provides the first human evidence that TRB-001, a novel alpha-synuclein vaccine, is safe and immunogenic in a Parkinson's disease patient. The induction of high-titer, high-avidity antibodies that specifically target aggregated alpha-synuclein, coupled with stable clinical scores and a reduction in symptomatic medication, offers a promising new avenue for disease-modifying therapy. While a single case, these findings suggest that active immunotherapy could potentially slow or halt the progression of PD by clearing pathological protein aggregates. The observed reduction in LEDD and resolution of impulse control disorder, though anecdotal, highlights the potential for improved quality of life. Further clinical trials are essential to validate these findings across a larger patient cohort and establish a standardized, usable protocol for this innovative vaccine.
trb-001
parkinson's-disease
alpha-synuclein
vaccine
immunotherapy
neurodegenerative